Boeing Secures $166.8 Million U.S. Navy Contract for P-8A Engineering and Software Support 
MOEX Russia Index Hits 3-Month High as Energy Stocks Lead Gains 
Global Markets React as Dollar Surges, Swiss Franc Rallies After U.S.-Israel Strike on Iran 
Netflix Declines to Raise Bid for Warner Bros. Discovery Amid Competing Paramount Skydance Offer 
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade 
FCC Approves Charter Communications’ $34.5 Billion Acquisition of Cox Communications 
Oil Prices Surge 13% as U.S.-Israel Strikes on Iran Spark Supply Fears 
Malta will gain from smart heritage 
Middle East Airspace Shutdown Disrupts Global Flights After U.S.-Israel Strikes on Iran 
China’s New Home Prices Post Sharpest Drop Since 2022 Amid Ongoing Property Slump 
Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates 
Australian Dollar Rallies on Hawkish RBA Outlook; Yen Slips as BOJ Faces Political Pressure 
Argentina Tax Reform 2026: President Javier Milei Pushes Lower Taxes and Structural Changes 
Japan Manufacturing PMI Jumps to Four-Year High as Global Demand Strengthens 
Greg Abel’s First Berkshire Hathaway Shareholder Letter Signals Continuity, Caution, and Capital Discipline 
Meta Signs Multi-Billion Dollar AI Chip Deal With Google to Power Next-Gen AI Models 
LG Chem Ltd. announced it set to buy AVEO Pharmaceuticals for $566 million or $15 per share in full cash. The South Korean chemical company headquartered in Seoul is aiming to purchase a 100% stake in the Boston-based company.
With the acquisition, LG Chem will expand its commercial footprint in the US market for a wide range of oncology therapies. The company also revealed on Tuesday, Oct. 18, that it will also use the deal to branch out to other related fields.
According to The Korea Times, AVEO Pharma developed FOTIVDA prescription medicine made for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). this drug was only approved in March 2021 by the U.S. Food and Drug Administration (FDA).
LG Chem said that this is the first time that a South Korean company is buying a firm that has been granted approval by the FDA for a new type of drug. As it acquires AVEO, the company is planning to invest in LG Chem Life Science Innovation Center so it can establish a special purpose company for the takeover of the US-based pharma firm.
Moreover, the deal will provide LG Chem’s Life Sciences unit with a commercial presence in the United States. This will also speed up the company’s efforts to deliver its continued growth.
The transaction is expected to close in early 2023, and as with any other buyout deals, this is still subject to customary closing conditions. It should be approved by AVEO’s shareholders and go through regulatory processes.
“With its track record of clinical success, deep pipeline of innovative therapies and continued growth trajectory following the successful commercialization of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences,” LG Chem’s chief executive officer, Shin Hak Cheol, said in a press release. “This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.
The CEO further said, “We remain focused on prudently investing in our R&D capabilities, continuing to build a leading portfolio of therapies and transforming lives through inspiring science and leading innovation.”
